MX2022015493A - Compuestos de imidazopiridazina y usos de los mismos. - Google Patents

Compuestos de imidazopiridazina y usos de los mismos.

Info

Publication number
MX2022015493A
MX2022015493A MX2022015493A MX2022015493A MX2022015493A MX 2022015493 A MX2022015493 A MX 2022015493A MX 2022015493 A MX2022015493 A MX 2022015493A MX 2022015493 A MX2022015493 A MX 2022015493A MX 2022015493 A MX2022015493 A MX 2022015493A
Authority
MX
Mexico
Prior art keywords
compounds
activity
imidazopyridazine compounds
alk2
alk2 inhibitors
Prior art date
Application number
MX2022015493A
Other languages
English (en)
Inventor
Jun Pan
Liangxing Wu
Yu Bai
Wenqing Yao
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MX2022015493A publication Critical patent/MX2022015493A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Dental Preparations (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Se describen compuestos de Fórmula (I), métodos de uso de los compuestos para inhibir la actividad de ALK2 y composiciones farmacéuticas que comprenden los compuestos. Los compuestos son útiles para tratar, prevenir o mejorar enfermedades o trastornos asociados con la actividad de ALK2, tales como el cáncer.
MX2022015493A 2020-06-12 2021-06-10 Compuestos de imidazopiridazina y usos de los mismos. MX2022015493A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063038410P 2020-06-12 2020-06-12
PCT/US2021/036839 WO2021252781A1 (en) 2020-06-12 2021-06-10 Imidazopyridazine compounds with activity as alk2 inhibitors

Publications (1)

Publication Number Publication Date
MX2022015493A true MX2022015493A (es) 2023-03-21

Family

ID=76971994

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015493A MX2022015493A (es) 2020-06-12 2021-06-10 Compuestos de imidazopiridazina y usos de los mismos.

Country Status (17)

Country Link
US (2) US11840546B2 (es)
EP (1) EP4165051A1 (es)
JP (1) JP2023530088A (es)
KR (1) KR20230025434A (es)
CN (1) CN115956081A (es)
AR (1) AR122587A1 (es)
AU (1) AU2021288107A1 (es)
BR (1) BR112022025191A2 (es)
CA (1) CA3184811A1 (es)
CL (1) CL2022003453A1 (es)
CO (1) CO2022017969A2 (es)
EC (1) ECSP22093652A (es)
IL (1) IL298248A (es)
MX (1) MX2022015493A (es)
PE (1) PE20230491A1 (es)
TW (1) TW202214660A (es)
WO (1) WO2021252781A1 (es)

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2413330A1 (en) 2000-06-28 2002-01-03 Smithkline Beecham P.L.C. Wet milling process
KR101150581B1 (ko) * 2007-07-26 2012-06-11 노파르티스 아게 유기 화합물
BRPI0817434A2 (pt) 2007-10-17 2015-06-16 Novartis Ag Composto orgânicos
JP5926727B2 (ja) 2010-07-28 2016-05-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換イミダゾ［１，２−ｂ］ピリダジン
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
CN103649093B (zh) 2011-05-06 2017-07-07 拜耳知识产权有限责任公司 取代的咪唑并吡啶和咪唑并哒嗪及其用途
WO2014160203A2 (en) 2013-03-14 2014-10-02 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
TW201718581A (zh) 2015-10-19 2017-06-01 英塞特公司 作為免疫調節劑之雜環化合物
ES2928856T3 (es) 2015-11-19 2022-11-23 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
MA44075A (fr) 2015-12-17 2021-05-19 Incyte Corp Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
UA126113C2 (uk) 2015-12-22 2022-08-17 Інсайт Корпорейшн Гетероциклічні сполуки як імуномодулятори
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2017222976A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Heterocyclic compounds as immunomodulators
WO2018013789A1 (en) 2016-07-14 2018-01-18 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
US20190218214A1 (en) 2016-09-14 2019-07-18 Vanderbilt University Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof
US11371744B2 (en) 2016-09-15 2022-06-28 Awi Licensing Llc Ceiling system with air movement
BR112019012957A2 (pt) 2016-12-22 2019-11-26 Incyte Corp derivados de tetra-hidroimidazo[4,5-c]piridina como indutores de internalização de pd-l1
US20180179179A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
AU2017382870B2 (en) 2016-12-22 2022-03-24 Incyte Corporation Benzooxazole derivatives as immunomodulators
US20180177784A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
CN110430880A (zh) 2017-01-18 2019-11-08 范德比尔特大学 作为选择性bmp抑制剂的稠合杂环化合物
WO2018165569A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Therapeutic compounds and methods
AU2019401649A1 (en) 2018-12-20 2021-07-08 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2

Also Published As

Publication number Publication date
TW202214660A (zh) 2022-04-16
US20240083918A1 (en) 2024-03-14
KR20230025434A (ko) 2023-02-21
ECSP22093652A (es) 2023-02-28
AU2021288107A1 (en) 2022-12-15
US20210388003A1 (en) 2021-12-16
CN115956081A (zh) 2023-04-11
EP4165051A1 (en) 2023-04-19
WO2021252781A1 (en) 2021-12-16
PE20230491A1 (es) 2023-03-23
CL2022003453A1 (es) 2023-05-26
AR122587A1 (es) 2022-09-21
CA3184811A1 (en) 2021-12-16
IL298248A (en) 2023-01-01
CO2022017969A2 (es) 2023-02-27
JP2023530088A (ja) 2023-07-13
US11840546B2 (en) 2023-12-12
BR112022025191A2 (pt) 2023-03-07

Similar Documents

Publication Publication Date Title
CR20220584A (es) Inhibidores de kras tricíclicos fusionados
MX2021009246A (es) Inmunomoduladores, composiciones y metodos de los mismos.
WO2018049152A8 (en) Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2023004923A (es) Compuestos heterociclicos como inmunomoduladores.
PH12020551927A1 (en) Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
CR20230310A (es) Inhibidores de prmt5
CR20240059A (es) Compuestos tricíclicos como inhibidores de kras.
IL165624A0 (en) Mitotic kinesin inhibitors
EP1492487A4 (en) INHIBITORS OF MITOTIC KINESIN
TW200510380A (en) Mitotic kinesin inhibitors
MX2023001997A (es) Compuestos biciclicos, composiciones y usos de los mismos.
PH12021551446A1 (en) Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
MX2021012501A (es) Inhibidores de complejo represivo polycomb 2 (prc2).
MX2022001004A (es) Inhibidores de enzimas.
MX2021006619A (es) Inhibidores de la tirosina quinasa, composiciones y sus metodos.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
PL1732926T3 (pl) Inhibitory kinezyn motorycznych
MX2021008667A (es) Derivado de pirrolopirimidina y composición farmacéutica para prevenir o tratar enfermedades relacionadas con la proteína quinasa que comprende el mismo como principio activo.
CR20230362A (es) Inhibidores de cdk2 y métodos de uso de los mismos
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
PH12019501642A1 (en) Novel compounds and their use in the treatment of schistosomiasis
MX2022015739A (es) Inhibidores alostericos de egfr y metodos de uso de estos.
WO2019036417A3 (en) Inhibition of ngly1 for the treatment of cancer